The Relationship Between Fetal Baseline Heart-rate and the Level of Acetyl-choline Esterase in Fetal Blood

NCT ID: NCT03478267

Last Updated: 2022-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

101 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-17

Study Completion Date

2021-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean section will be recruited for the study. Data regarding maternal resting heart rate and fetal baseline heart rate as depicted on the monitor will be collected. A blood sample will be acquired from the parturient and the umbilical cord as well as a sample from the placenta will be obtained. Levels of Acetyl Choline Esterase (AChE) will be determined from all aforementioned samples. Statistical correlation between fetal baseline heart rate and fetal and maternal AChE levels will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pregnant women between 32-41 weeks' gestation designated for either vaginal birth or cesarean section will be recruited for the study. After signing an informed consent, data regarding maternal resting heart rate and fetal baseline heart rate as depicted on the monitor will be collected.

Patients will be divided into 2 equal groups according to fetal baseline heart rate:

1. st group-fetal heart rate between 110-130 beats per minute (bpm).
2. nd group-fetal heart rate between 140-160 bpm. A blood sample will be acquired from the parturient and the umbilical cord as well as a sample from the placenta will be obtained. Levels of Acetyl Choline Esterase (AChE) will be determined from all aforementioned samples. Statistical correlation between fetal baseline heart rate and fetal and maternal AChE levels will be assessed.

Data regarding demographic, medical and obstetric information of the participants will be obtained from the hospital's electronic records.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fetal Heart Failure (Disorder)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fetal heart rate 110-130 bpm

Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.

AChE levels

Intervention Type DIAGNOSTIC_TEST

AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.

Fetal heart rate 140-160 bpm

Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.

AChE levels

Intervention Type DIAGNOSTIC_TEST

AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AChE levels

AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women between 32 and 41 weeks' gestation undergoing either vaginal or cesarean delivery with a fetal baseline heart rate of 110-130 beats per minute and 140-160 beats per minute.

Exclusion Criteria

1. Delivery before 32 weeks of gestation
2. Maternal bradycardic (\<60) or tachycardic (\>100) resting heart rate.
3. Fetal bradycardia (\<110) or tachycardia (\>160).
4. Suspected chorioamnionitis
5. Maternal diseases which can affect her heart rate such as:

1. Cardiac disease (including arrhythmias)
2. Diseases of the thyroid gland
3. Rheumatic diseases
6. Use of medication which alters heart rate such as:

1. Beta blockers
2. Beta agonists
3. Cocaine, amphetamines
7. Use of Pethidine and Phenergan during delivery
Minimum Eligible Age

18 Years

Maximum Eligible Age

44 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rambam Health Care Campus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vered Lamhot MD

Primary investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vered Lamhot, MD

Role: PRINCIPAL_INVESTIGATOR

Rambam Health Care Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rambam hospital

Haifa, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0584-16-RMB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nesiritide Use Following Cardiac Surgery in Infants
NCT00281671 TERMINATED PHASE1/PHASE2
Nesiritide in Chronic Heart Failure
NCT00145873 TERMINATED PHASE2
Myocardial Deformation Before and After Birth
NCT04060381 ACTIVE_NOT_RECRUITING
Single Ventricle Outcome
NCT00308217 COMPLETED